For example, co-targeting of anti-apoptotic proteins BCL-XL or MCL-1 and MEK promotes tumor regression in KRAS-mutant tumor models compared with MEK targeting alone [144, 145]. The gene discussed is BCL2L1; the disease is neoplasm.